#### PATENT APPLICATION

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q94183

Yosuke FUNAKOSHI, et al.

Appln. No.: 10/574,489

Group Art Unit: 1617

Confirmation No.: 9109

Examiner: CARTER, KENDRA D

Filed: July 25, 2006

For: METHOD FOR PREVENTING AND/OR TREATING NEURODEGENERATIVE

**DISEASES** 

# INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

#### MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed after the later of three months from the application's filing date and the mailing date of the first Office Action on the merits, but before a Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution in the application (whichever is earlier), and therefore Applicant is filing concurrently herewith a Statement Under 37 C.F.R. § 1.97(e). No fee under 37 C.F.R. § 1.17(p) is required.

INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. §§ 1.97 and 1.98

U.S. Appln. No.: 10/574,489

Attorney Docket No.: Q94183

The present Information Disclosure Statement is being filed thirty days or fewer from the

communication from a foreign patent office and a Statement Under 37 C.F.R. §1.704(d) is

attached.

Applicant encloses herewith a copy of a Communication from a foreign patent office in a

counterpart application citing such documents (A Supplementary European Search Report issued

in application No. 04773691.3 - 2123 dated January 12, 2010), together with an English-

language version (if not already included) of at least that portion of the Communication

indicating the degree of relevance found by the foreign patent office.

Applicant also notes that a copy of 'JOURNAL OF CEREBRAL BLOOD FLOW AND

METABOLISM' JUN 2002, Vol. 22, No. 6, June 1, 2002, pages 723-734, was previously cited

by the examiner in USPTO Office Action dated October 14, 2009.

The submission of the listed documents is not intended as an admission that any such

document constitutes prior art against the claims of the present application. Applicant does not

waive any right to take any action that would be appropriate to antedate or otherwise remove any

listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue

Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any

overpayments to said Deposit Account.

Respectfully submitted,

Registration No. 30,951

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON DC SUGHRUE/265550

65565

CUSTOMER NUMBER

Date: February 12, 2010

2

#### PATENT APPLICATION

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q94183

Yosuke FUNAKOSHI, et al.

Appln. No.: 10/574,489

Group Art Unit: 1617

Confirmation No.: 9109

Examiner: CARTER, KENDRA D

Filed: July 25, 2006

For: METHOD FOR PREVENTING AND/OR TREATING NEURODEGENERATIVE

DISEASES

## STATEMENT UNDER 37 C.F.R. § 1.97(e)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Sir:

The undersigned hereby states, upon information and belief:

That each item of information contained in the Information Disclosure Statement filed concurrently herewith was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of said Information Disclosure Statement.

Respectfully submitted,

Registration No. 30,951

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON DC SUGHRUE/265550

65565
CUSTOMER NUMBER

Date: February 12, 2010

#### PATENT APPLICATION

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q94183

Yosuke FUNAKOSHI, et al.

Appln. No.: 10/574,489

Group Art Unit: 1617

Confirmation No.: 9109

Examiner: CARTER, KENDRA D

Filed: July 25, 2006

For: METHOD FOR PREVENTING AND/OR TREATING NEURODEGENERATIVE

**DISEASES** 

# STATEMENT UNDER 37 C.F.R. § 1.704(d)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Sir:

The undersigned hereby states, upon information and belief:

That each item of information contained in the Information Disclosure Statement filed concurrently herewith was first cited in a communication from a foreign patent office in a counterpart foreign application, and that the communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of said Information Disclosure Statement.

Respectfully submitted,

Registration No. 30,951

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON DC SUGHRUE/265550

65565 CUSTOMER NUMBER

Date: February 12, 2010